CGFNS International
28.6.2024 06:32:25 CEST | ACCESS Newswire | Press release
Exam registration for Certified Global Nurse - Rehabilitation (CGN-R) to open in July, handbook available now
PHILADELPHIA, PA / ACCESSWIRE / June 27, 2024 / CGFNS International, a worldwide leader in international credentials evaluation to support health worker careers, has launched the first-ever global credential for registered nurses working in rehabilitation, habilitation or restorative care.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.The Certified Global Nurse - Rehabilitation (CGN-R) credential is intended to advance and improve services for the more than two billion people worldwide who need this care. It has been developed specifically for eligible registered nurses worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination.
The exam was created in collaboration with a global task force of more than 60 rehabilitation nursing experts from 17 countries who contributed their knowledge and guidance to develop a global competency framework for rehabilitation nursing and to create a test blueprint for a competency-based exam. The task force's framework is aligned with the Rehabilitation Competency Framework established by the World Health Organization.
Accordingly, those who earn the CGN-R credential will be able to show their employers, prospective employers and others that they have been assessed against a global industry standard for rehabilitation care and that their expertise has been benchmarked against other nurses in rehab care worldwide.
Registration for the CGN-R exam will open in July, with testing dates to be scheduled for November. Registered (first-level) nurses with at least two years' work experience in rehabilitation care are eligible to apply. Further details on eligibility requirements, exam topics and how to apply can be found in the exam handbook, now available at the CGFNS website.
"This will be the first global specialty certification offered anywhere for rehab nursing. It represents a huge shift for our global health workforce, for whom specialty credentials are often out of reach and require migration to the countries that offer them. The CGN-R certification will enable rehabilitation nurses everywhere to demonstrate a validated specialty skillset to their employers, carry the credential with them wherever they want to work in the world, and advance their career opportunities," said Julia To Dutka, Chief of the CGFNS Global Health Workforce Development Institute, which is leading the initiative to develop this and other global credentials for the rehabilitation workforce.
"Provider certifications enable health systems and hospitals to confidently identify the most well-equipped workforce candidates to meet their burgeoning care needs. At a time when qualified interdisciplinary care teams are critically needed in rehabilitation care, the CGN-R establishes a global standard against which employers can set the bar for provider qualifications within their health systems," said Terrence Carolan, Managing Director of Medical Rehabilitation and Aging Services of CARF International, an independent, nonprofit organization that accredits more than 66,000 rehabilitation and other health and human service providers on five continents and that has advised CGFNS in developing the CGN-R credential.
Nurses who sit for the initial CGN-R exam in November will receive a discount on exam fees.
CGFNS is also offering an early adopter program for hospitals, health systems or rehabilitation organizations that would like to invest in specialty certification for their rehab nurse workforce. The program includes opportunities to host the CGN-R exam onsite for their rehab nursing teams and earn an early adopter's badge for organizational recognition.
Information on additional credentials for other health workers in a rehabilitative/habilitative/restorative environment - including physical and occupational therapists, speech-language pathologists and rehab technicians, among others - will be made available in the coming months.
More information on the program can be found at https://www.cgfns.org/services/certification/global-rehabilitation/
About CGFNS International, Inc.
Founded in 1977 and based in Philadelphia, CGFNS International is an immigration-neutral not-for-profit organization proudly serving as the world's largest credentials evaluation organization for the nursing and allied health professions. CGFNS International is an NGO in Consultative Status with the United Nations Economic and Social Council (ECOSOC) and is a member of the Conference of NGOs in Consultative Relationship with the United Nations (CoNGO).
Contact Information
David St. John
dstjohn@cgfns.org
SOURCE: CGFNS International
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release
ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the
Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release
HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy
Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom